Active Surveillance

Although aggressive treatment may be the right path for certain patients upon positive diagnosis, active surveillance may be the best decision for those patients with slow-growing, organ-confined disease.

 

Active surveillance involves carefully monitoring your patient for signs of progression, which may include routine prostate-specific antigen (PSA) tests and digital rectal examinations (DREs). Based on these test results (and other factors, as appropriate), a repeat biopsy may also be warranted. If the cancer shows no sign of worsening, no aggressive treatment may be necessary.
 
Studies show that many more men are aggressively treated for prostate cancer than is necessary, resulting in unneeded life-altering side-effects and financial hardship. Approximately 30%-40% of men who have undergone surgical or other therapeutic interventions to treat their prostate cancers likely had indolent, slow-growing tumors that would never have become a threat to the man’s lifespan or health.1 The key is to identify those patients who in fact do not need to undergo aggressive treatment to preserve their health.

Advanced prognostics, such as ProMark, can provide the additional information needed to further stratify your patients and enable confident decision-making in aggressive treatment vs. active surveillance.

Make an informed decision.

  • Learn more about ProMark (for Gleason 3+3 and 3+4 patients)
  • Learn more about PTEN/ERG (for Atypical/HGPIN patients)
 
  1. Prostate Cancer Foundation, www.pcf.org, Improving Methods to Identify Indolent Versus Aggressive Prostate Cancer

 

Next: Our Lab Services Overview
ProMark: Proteomics Prognostic Test for Prostate Cancer

ProMark, a first-of-its-kind  proteomic prognostic test for biopsy Gleason Scores 3+3 and 3+4.

Gain CONFIDENCE for better treatment decisions.

                                                                  LEARN MORE
 




Improve your biopsy decisions.
Reduce the number of unnecessary repeat biopsies.

                                                                  LEARN MORE